Why does one medicine have two names?
Semaglutide has two injectable brand names because the manufacturer sought separate approvals for two different jobs, at two different dose ranges. Ozempic was approved first, on December 5, 2017, according to its Drugs@FDA record. Wegovy followed on June 4, 2021, per its own Drugs@FDA record.
| Ozempic | Wegovy | |
|---|---|---|
| Approved for | Blood sugar control in adults with type 2 diabetes, plus heart and kidney risk reduction in that group | Weight reduction and long-term maintenance, heart risk reduction in adults with heart disease and excess weight, and a fatty liver disease called MASH |
| Need diabetes? | Yes | No |
| Top weekly dose | 2 mg | 2.4 mg usual maintenance, up to 7.2 mg for selected adults |
| Use for weight alone | Off-label | On-label |
The Ozempic label lists only diabetes-related indications, and its maximum recommended dose is 2 mg once weekly. The Wegovy label covers adults with obesity, and adults with overweight plus at least one weight-related condition, with no diabetes requirement.
Who was Wegovy tested in?
Wegovy was built and tested for people without diabetes. In the main 68-week trial described on the label, adults qualified with a BMI of 30 or more, or 27 to 29.9 plus at least one weight-related condition such as treated or untreated high cholesterol or high blood pressure. People with type 2 diabetes were excluded.
Everyone in that trial also got counseling for a reduced-calorie diet and at least 150 minutes of activity a week. On that background, average weight loss was 14.9% with semaglutide and 2.4% with placebo, and 66.1% of people on the drug lost at least a tenth of their body weight. Diabetes is not a barrier either. The label also reports a 72-week trial of the 7.2 mg dose in adults with type 2 diabetes and obesity, where average weight loss was 13.2% against 3.8% on placebo. Weight loss tends to be somewhat smaller in people with diabetes, which is one more reason the dose plan is individual. Our semaglutide medication page covers the drug in more depth.
Is using Ozempic for weight loss the same thing?
It is the same molecule, but not the same plan. Ozempic for weight alone is off-label, its pens stop at 2 mg, and coverage decisions often hinge on the diagnosis the drug is approved for. Our page on insurance coverage for semaglutide weight loss explains why that matters for out-of-pocket cost.
The label you are treated under also shapes the dose ladder and the evidence behind your plan. For a man without diabetes, the Wegovy label is the one written for his situation. Men who prefer a pill have an option too, since the Wegovy label now includes a daily tablet; our comparison of oral and injected semaglutide weighs the two.
Does prediabetes change anything?
Prediabetes does not make semaglutide a diabetes treatment, but it often counts in your favor. The NIDDK describes the usual threshold for weight-management medicines as a BMI of 30 or more, or 27 or more with a weight-related health problem such as high blood pressure or type 2 diabetes. For a man with a BMI between 27 and 30, your provider decides whether a condition such as prediabetes is the weight-related problem that applies, and documents why.
Weight loss itself tends to improve blood sugar, and our answer on whether semaglutide can reverse prediabetes looks at that evidence.
How Ultimate Male evaluates you without a diabetes diagnosis
At our San Gabriel and Downey clinics, the evaluation is the same whether or not you have diabetes: same-day labs including A1c, a body composition scan and a one-on-one consultation with a PA-C or MD. If you qualify, your provider explains which product you would use, how its label applies to you and what the first months look like.
If you do have diabetes, your medicines are reviewed closely, because insulin and sulfonylureas raise the chance of low blood sugar alongside semaglutide. Read how the medical weight loss program runs, or ask your questions on a free 10-minute call at 626-319-5261.
